What is KPC Pharmaceuticals,Inc.'s (600422.SS) StockRank?

MoatMap's StockRank for KPC Pharmaceuticals,Inc. (600422.SS) is 24/100, with a Sell signal. This is a composite score combining Quality (43), Value (36), and Momentum (35) factor ranks across MoatMap's 20,000+ stock universe.

Does KPC Pharmaceuticals,Inc. have an economic moat?

KPC Pharmaceuticals,Inc. (600422.SS) has a Quality factor score of 43/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is KPC Pharmaceuticals,Inc. a buy, hold, or sell?

MoatMap's current signal for KPC Pharmaceuticals,Inc. (600422.SS) is Sell, based on a StockRank of 24/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is KPC Pharmaceuticals,Inc. in?

KPC Pharmaceuticals,Inc. (600422.SS) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (China).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

600422.SS

SELLREMOVE

KPC Pharmaceuticals,Inc. · Healthcare · China · $999M · Avg Vol: $12M/d

StockRank

P/E (TTM)

56.7x

ROE

2.4%

D/E

0.2x

Dividend %

2.1%

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

KPC Pharmaceuticals focuses on traditional Chinese medicine, which lacks a global runway and is highly subject to domestic regulatory price controls and raw material cost volatility.

COMPANY DESCRIPTION

KPC Pharmaceuticals is a prominent Chinese pharmaceutical company specializing in natural plant-based medicines, traditional Chinese medicine (TCM), and chemical drugs. The company is a global leader in the industrialization of artemisinin-based antimalarial drugs and holds a dominant position in cardiovascular treatments derived from Panax notoginseng. Its strong brand heritage, proprietary formulations, and extensive distribution network in China form a robust competitive moat.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	1.2B	1.2B	1.2B	972M	-7.4%
EPS	0.08	0.10	0.13	0.07	-3.4%
Shares	758M	758M	757M	757M	-0.2%
Debt	168M	133M	123M	249M	13.9%
Equity	736M	970M	776M	793M	2.5%
Op CF	38M	111M	119M	43M	4.4%
Inv CF	-35M	-48M	13M	-94M	—
Fin CF	10M	-91M	-19M	-97M	—

PRICE (1M)-12.0%

SMA 50SMA 200

$1.24

RSI (14)

46.9

52W High

$2.31

From 52W High

0.5%

SCORE BREAKDOWN

Quality

ROIC

6.6%61.9

ROE

2.4%49.0

GP/Assets

18.0%42.1

Op. Margin

-20.5%26.2

FCF/Assets

-7.3%31.8

Piotroski

—28.7

Int. Cover

10.4x65.0

D/E Ratio

0.24x49.0

Current Ratio

2.09x38.8

Value

P/E (TTM)

56.7x17.2

EV/EBITDA

89.5x3.6

P/FCF

—N/A

P/B

1.2x73.4

P/S

1.1x82.1

Div Yield

2.1%52.6

Momentum

52W High %

54%28.2

RS 6M

-44%25.8

SMA 50/200

0.79x11.5

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

—98.1

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$999M

P/E (Forward)

6.2x

Gross Margin

36.3%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 600422.SS are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
600422.SS	KPC Pharmaceuticals,Inc.(you)	$999M	24	SELL
002940.SZ	Zhejiang AngLiKang Pharmaceutical CO.,LTD.	$1.0B	25	SELL
300702.SZ	Zhejiang Tianyu Pharmaceutical Co., Ltd.	$989M	26	SELL
603567.SS	Heilongjiang ZBD Pharmaceutical Co., Ltd.	$994M	26	SELL
688276.SS	Changchun BCHT Biotechnology Co.	$975M	21	SELL
600129.SS	Chongqing Taiji Industry(Group) Co.,Ltd	$1.2B	23	SELL
688621.SS	Beijing Sun-Novo Pharmaceutical Research Co., Ltd.	$894M	26	SELL
688221.SS	Frontier Biotechnologies Inc.	$1.1B	21	SELL
300363.SZ	Porton Pharma Solutions Ltd.	$1.2B	26	SELL
600812.SS	North China Pharmaceutical Company.Ltd	$1.2B	21	SELL

Peer medians: ROE 4.8% · P/E 27.6x · Gross margin 53.1%

KPC Pharmaceuticals,Inc. (600422.SS) — Stock Score Summary

KPC Pharmaceuticals,Inc. (600422.SS) has a MoatMap StockRank of 24/100 based on Quality (43/100), Value (36/100), and Momentum (35/100) factor scores. The current signal is SELL. KPC Pharmaceuticals focuses on traditional Chinese medicine, which lacks a global runway and is highly subject to domestic regulatory price controls and raw material cost volatility.

Key Financial Metrics

Price	$1.24
Market Cap	$999M
P/E (TTM)	56.67
P/E (Forward)	6.16
Price/Book	1.23
Return on Equity	2.4%
Return on Invested Capital	6.6%
Debt/Equity	23.77
Gross Margin	36.3%
Operating Margin	-20.5%
Revenue Growth	-48.0%
Dividend Yield	2.1%
Free Cash Flow	$-19M

KPC Pharmaceuticals,Inc. operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is KPC Pharmaceuticals,Inc.’s (600422.SS) StockRank?: MoatMap’s StockRank for KPC Pharmaceuticals,Inc. (600422.SS) is 24/100, with a Sell signal. It is a composite of Quality (43), Value (36), and Momentum (35) factor ranks across MoatMap’s 20,000+ stock universe.
Does KPC Pharmaceuticals,Inc. have an economic moat?: KPC Pharmaceuticals,Inc. (600422.SS) has a Quality factor score of 43/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is KPC Pharmaceuticals,Inc. a buy, hold, or sell?: MoatMap’s current signal for KPC Pharmaceuticals,Inc. (600422.SS) is Sell, based on a StockRank of 24/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is KPC Pharmaceuticals,Inc. in?: KPC Pharmaceuticals,Inc. (600422.SS) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (China).